Trial participation and vaccine desirability for Vi polysaccharide typhoid fever vaccine in Hue City, Viet Nam

被引:15
|
作者
Kaljee, Linda M. [1 ]
Pham, Van
Son, Nguyen Dinh
Hoa, Nguyen Thai
Thiem, Vu Dinh
Canh, Do Gia
Kim Thoa, Le Thi
Ali, Mohammad
Ochiai, Rion Leon
Danovaro-Holliday, M. Carolina
Acosta, Camilo J.
Stanton, Bonita
Clemens, John
机构
[1] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA
[2] Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA
[3] Prov Prevent Med Ctr, Hue City, Thua Thien, Vietnam
[4] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam
[5] Ha Noi Med Univ, Hanoi, Vietnam
[6] Int Vaccine Inst, Seoul, South Korea
[7] Wayne State Univ, Sch Med, Carman & Ann Adams Dept Pediat, Detroit, MI USA
关键词
children/adolescents; enteric disease; vaccination; typhoid fever; Viet Nam;
D O I
10.1111/j.1365-3156.2006.01751.x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVES To identify demand for Vi typhoid fever vaccine for school-age children; obstacles and enabling factors for vaccine delivery; and socio-behavioural factors associated with trial participation and possible predictors of future vaccine acceptance, in Hue City, Viet Nam. METHODS Pre- and post-trial surveys of randomly selected households with children aged 6-17 years. Simple multinomial logistic analyses for ratios of relative risks (RRR) and significance on trial participation by demographics and variables related to typhoid fever, vaccination, and pre-trial experiences with information and consents. Multiple logistic regressions to assess differences in participation based on child's characteristics. RESULTS As many as 62.6% of households let all school age children participate, 10.2% let some participate, and 26.8% let none of their children participate in the trial. Factors associated with all children participating included past use of healthcare facilities (RRR, 0.45; 95% CI, 0.24-0.83), knowledge of vaccines (RRR, 0.17; 95% CI, 0.03-0.86), and perceived causes of typhoid fever (RRR, 0.90; 95% CI, 0.81-0.99). Factors associated with some children participating included utilization of healthcare facilities (RRR, 0.08; 95% CI, 0.01-0.66) and perceived severity of typhoid fever (RRR, 0.64; 95% CI 0.46-0.88). Participation was associated with satisfaction regarding pre-vaccination information and consent procedures. Children and adolescents were active decision-makers. Only 14 of 461 (2.2%) respondents would not use the Vi vaccine in the future for their child(ren). CONCLUSIONS Inter-related factors contribute to participation in a clinical vaccine trial, which may differ from desire to participate in a public health campaign. Educational campaigns need to be targeted to children and adolescents, and consideration for assent procedures for minors. Obtaining informed consent may affect trial participation within a social and political system unaccustomed to these procedures.
引用
收藏
页码:25 / 36
页数:12
相关论文
共 50 条
  • [21] A recently developed typhoid Vi polysaccharide vaccine - Rationale and clinical profile
    Zuckerman, JN
    BIODRUGS, 2001, 15 (Suppl 1) : 1 - 4
  • [22] TYPHIM-VI VACCINE AGAINST TYPHOID-FEVER - A CLINICAL-TRIAL IN KENYA
    MIRZA, NB
    WAMOLA, IA
    ESTAMBALE, BA
    MBITHI, E
    POILLET, M
    EAST AFRICAN MEDICAL JOURNAL, 1995, 72 (03) : 162 - 164
  • [23] Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: A cluster randomized trial in Karachi, Pakistan
    Khan, M. Imran
    Soofi, Sajid Bashir
    Ochiai, R. Leon
    Habib, Mohammad Atif
    Sahito, Shah Muhammad
    Nizami, S. Qamaruddin
    Acosta, Camilo J.
    Clemens, John D.
    Bhutta, Zulfiqar A.
    VACCINE, 2012, 30 (36) : 5389 - 5395
  • [24] Assessment of vaccine herd protection in a cluster-randomised trial of Vi conjugate vaccine against typhoid fever: results of further analysis
    Khanam, Farhana
    Kim, Deok Ryun
    Liu, Xinxue
    Voysey, Merryn
    Pitzer, Virginia E.
    Zaman, K.
    Pollard, Andrew J.
    Qadri, Firdausi
    Clemens, John D.
    ECLINICALMEDICINE, 2023, 58
  • [25] Reactogenicity and Immunogenicity ofa Single Dose of a Typhoid Vi Polysaccharide Vaccine in Adolescents
    Arthi Ramkissoon
    Prakash Jugnundan
    BioDrugs, 2001, 15 : 21 - 26
  • [26] Field effectiveness of Vi polysaccharide typhoid vaccine in the People's Republic of China
    Arya, SC
    JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (06): : 845 - 845
  • [28] Immunogenicity and safety of vi capsular polysaccharide typhoid vaccine in healthy persons in Korea
    Lim, Sang-Min
    Jung, Hahn-Sun
    Kim, Min Ja
    Park, Dae-Won
    Kim, Woo-Joo
    Cheong, Hee-Jin
    Park, Seung-Chul
    Lee, Kwang-Chul
    Shin, Young-Kyoo
    Tan, Hyun Kwang
    Kim, Sang-Lin
    Sohn, Jang Wook
    JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2007, 17 (04) : 611 - 615
  • [29] An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: Estimation of the field effectiveness of Vi polysaccharide typhoid vaccine
    Yang, HH
    Kilgore, PE
    Yang, LH
    Park, JK
    Pan, YF
    Kim, YD
    Lee, YJ
    Xu, ZY
    Clemens, JD
    JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (12): : 1775 - 1780
  • [30] Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow-up
    Acosta, CJ
    Yang, HH
    Wang, N
    Gao, Q
    Deng, Q
    Ma, XL
    Zhou, BD
    Wei, L
    Danovaro-Holliday, MC
    Ochiai, RL
    Wang, XY
    Kim, DR
    Xu, ZY
    Dong, BQ
    Galindo, CM
    Clemens, JD
    VACCINE, 2005, 23 (48-49) : 5618 - 5623